No connection

Search Results

PAVM

BEARISH
$9.11 Live
PAVmed Inc. · NASDAQ
Target $40.5 (+344.6%)
$6.0 52W Range $28.44
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$57.53M
P/E
N/A
ROE
-32.3%
Profit margin
564.8%
Debt/Equity
0.6
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
PAVM exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9 and a catastrophic Current Ratio of 0.17, indicating a severe liquidity crisis. While revenue growth is nominally high (420%), the operational efficiency is non-existent with an operating margin of -13,082.69% and negative gross margins. There is a profound disconnect between the fundamental collapse (99.5% 5-year price decline) and the optimistic analyst target price of $40.50. The company is currently operating in a state of extreme financial fragility with no evidence of sustainable profitability.

Key Strengths

Significant year-over-year revenue growth (420%)
Price/Book ratio (0.91) suggests the stock is trading near its accounting book value
Recent earnings surprises have been positive relative to very low analyst expectations
Low Debt/Equity ratio (0.60) compared to healthcare sector average
Strong buy recommendation from a small subset of analysts

Key Risks

Severe liquidity risk with a Current Ratio of 0.17 (cannot cover short-term obligations)
Extreme operational inefficiency evidenced by -13,082% operating margin
Negative gross margins indicate the cost of goods exceeds the selling price
Total collapse of long-term shareholder value (-99.5% over 5 years)
Absurdly high Price/Sales ratio (810.32) indicating extreme overvaluation relative to revenue
AI Fair Value Estimate
Based on comprehensive analysis
$6.0
-34.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
9
Weak
Value
10
Future
30
Past
5
Health
0
Dividend
0
AI Verdict
Critical Distress
Key drivers: Piotroski F-Score 0/9, Liquidity crisis (Current Ratio 0.17), Negative Gross/Operating Margins, Extreme 5-year price decay
Confidence
90%
Value
10/100

Ref P/E N/A, P/S 810.32, P/B 0.91

Positives
  • P/B ratio is slightly below 1.0
Watchpoints
  • P/S ratio of 810.32 is unsustainable
  • No Graham Number available due to lack of earnings
Future
30/100

Ref Revenue Growth 420%

Positives
  • High YoY revenue growth
  • Aggressive analyst price targets
Watchpoints
  • Negative forward P/E
  • Lack of a path to operational profitability
Past
5/100

Ref 5Y Change -99.5%

Positives
  • Recent earnings beats (though estimates were deeply negative)
Watchpoints
  • 5-year return of -99.5%
  • Consistent history of heavy losses
Health
0/100

Ref Piotroski F-Score, Current Ratio

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 0/9
  • Current Ratio 0.17
  • Quick Ratio 0.13
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$9.11
Analyst Target
$40.5
Upside/Downside
+344.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PAVM and closest competitors.

Updated 2026-04-16
PAV
PAVmed Inc.
Primary
5Y
-99.5%
3Y
-95.5%
1Y
-55.3%
6M
-38.4%
1M
-12.3%
1W
-6.5%
DCG
DocGo Inc.
Peer
5Y
-94.3%
3Y
-93.1%
1Y
-77.6%
6M
-55.1%
1M
-15.2%
1W
-9.4%
MDA
Spectral AI, Inc.
Peer
5Y
-81.1%
3Y
-87.0%
1Y
+48.0%
6M
-16.3%
1M
+40.1%
1W
+11.4%
BTM
biote Corp.
Peer
5Y
-85.2%
3Y
-74.7%
1Y
-54.1%
6M
-47.5%
1M
-16.8%
1W
+10.4%
LUN
Pulmonx Corporation
Peer
5Y
-96.7%
3Y
-86.8%
1Y
-73.4%
6M
-9.4%
1M
-14.3%
1W
+5.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-3.32
PEG Ratio
N/A
P/B Ratio
0.91
P/S Ratio
810.32
EV/Revenue
1154.08
EV/EBITDA
-3.78
Market Cap
$57.53M

Profitability

Profit margins and return metrics

Profit Margin 564.79%
Operating Margin -13082.7%
Gross Margin -207.04%
ROE -32.34%
ROA -39.23%

Growth

Revenue and earnings growth rates

Revenue Growth +420.0%
Earnings Growth N/A
Q/Q Revenue Growth +420.0%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.6
Moderate
Current Ratio
0.17
Weak
Quick Ratio
0.13
Poor
Cash/Share
$0.31

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
-63.5%
Op. Margin
-12784.6%
Net Margin
-2428.8%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.49x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-30
$-1.05
+76.7% surprise
2025-11-13
$-0.6
+90.0% surprise
2025-08-14
$-1.5
+80.0% surprise

Healthcare Sector Comparison

Comparing PAVM against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-32.34%
This Stock
vs
-101.52%
Sector Avg
-68.1% (Below Avg)
Profit Margin
564.79%
This Stock
vs
-12.47%
Sector Avg
-4629.5% (Weaker)
Debt to Equity
0.6
This Stock
vs
3.4
Sector Avg
-82.4% (Less Debt)
Revenue Growth
420.0%
This Stock
vs
124.21%
Sector Avg
+238.1% (Fast Growth)
Current Ratio
0.17
This Stock
vs
4.56
Sector Avg
-96.2% (Weaker)

Similar Companies

Peer comparison within the same industry

PAVM PAVmed Inc.
BEARISH
Mkt Cap
$58M
P/E
-
ROE
-32.3%
Price
$9.11
DCGO DocGo Inc.
BEARISH
Mkt Cap
$56M
P/E
-
ROE
-89.0%
Price
$0.57
 Compare with PAVM
MDAI Spectral AI, Inc.
BEARISH
Mkt Cap
$59M
P/E
-
ROE
-%
Price
$1.85
 Compare with PAVM
BTMD biote Corp.
NEUTRAL
Mkt Cap
$56M
P/E
2.0
ROE
-%
Price
$1.49
 Compare with PAVM
LUNG Pulmonx Corporation
BEARISH
Mkt Cap
$61M
P/E
-
ROE
-77.2%
Price
$1.44
 Compare with PAVM

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

MCGRATH DENNIS M
President
Stock Award
2026-04-02
180,000 shares
AKLOG LISHAN
Chief Executive Officer
Stock Award
2026-04-02
350,000 shares
GLENNON MICHAEL J
Director
Stock Award
2026-04-02
13,930 shares
AGRAWAL SUNDEEP
Director
Stock Award
2026-04-02
13,930 shares
WHITE DEBRA JAYNE
Director
Stock Award
2026-04-02
13,930 shares
O'NEIL SHAUN
Chief Operating Officer
Stock Award
2026-04-02
110,000 shares
BAXTER TIMOTHY E
Director
Stock Award
2026-04-02
13,930 shares
GORDON MICHAEL ADAM
General Counsel
Stock Award
2026-04-02
110,000 shares
LEE VICTORIA TOU-HO
Officer
Stock Award
2026-04-02
70,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-30

PAVM filed an 8-K on March 30, 2026, likely to announce its first-quarter financial results.

8-K
8-K
2026-03-27
10-K
FORM 10-K
2026-03-27

PAVM submitted its annual 10-K filing on March 27, 2026, which includes disclosures regarding its business operations, risk factors, and financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

DEF 14A
DEF 14A
2026-02-24

PAVM filed a definitive proxy statement on February 24, 2026, providing shareholders with necessary information to vote on matters at the company's annual meeting.

8-K
8-K
2026-02-04

PAVM filed a current report on February 4, 2026, likely announcing its year-end financial results.

8-K
8-K
2026-01-23

PAVM filed a current report on January 23, 2026, likely announcing its financial results or a material corporate update.

8-K
8-K
2025-12-30
8-K
8-K
2025-12-05
8-K
8-K
2025-11-13

PAVM filed an 8-K on November 13, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-11-12

PAVM filed its quarterly 10-Q report on November 12, 2025. As no specific financial data or risk disclosures were provided in the excerpts, the filing serves as the primary source for the company's current financial performance and operational risks.

DEF 14A
DEF 14A
2025-10-31
8-K
8-K
2025-09-11
10-Q
10-Q
2025-08-14
8-K
8-K
2025-08-14
8-K
8-K
2025-07-30
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
2 analysts
Ascendiant Capital
2026-04-09
Maintains
Buy Buy
Ascendiant Capital
2025-12-10
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning PAVM from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile